^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-DOTA-girentuximab (TLX250)

    i
    Other names: TLX250, Lu-177-DOTA-cG250
    Associations

    News

    Trials
    Company:
    Telix
    Drug class:
    Ionizing radiation emitter, Carbonic anhydrase IX inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors (clinicaltrials.gov)
    P1b, N=36, Recruiting, Telix International Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CA9 (Carbonic anhydrase 9)
    |
    peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250)
    12ms
    Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors (clinicaltrials.gov)
    P1b, N=36, Not yet recruiting, Telix International Pty Ltd
    New P1 trial
    |
    CA9 (Carbonic anhydrase 9)
    |
    peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250)
    1year
    89Zr-DFO-girentuximab for PET/CT Imaging of Indeterminate Renal Masses - Results from Phase 3 ZIRCON Study (AUA 2023)
    Coprimary objectives were to evaluate both the sensitivity and specificity of TLX250-CDx PET/CT imaging in detecting ccRCC in patients with IDRM, using histology as standard of truth. 89 Zr-DFO-girentuximab PET/CT is well tolerated and can accurately and noninvasively identify and characterize IDRMs, showing promising utility for guiding surgical and treatment decisions.
    P3 data • Late-breaking abstract
    |
    CA9 (Carbonic anhydrase 9)
    |
    CA9 expression
    |
    177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)
    over1year
    89Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX. (ASCO-GU 2023)
    89Zr-DFO-girentuximab (hereafter referred to as TLX250-CDx) is a diagnostic radiopharmaceutical for PET imaging that targets CAIX and has demonstrated clinical success in ccRCC imaging. Statistics will be descriptive with no formal hypothesis. The study is ongoing.
    IO biomarker
    |
    CA9 (Carbonic anhydrase 9)
    |
    CA9 expression
    |
    177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)